Literature DB >> 35646215

Optimal indicator for changing the filter during the continuous renal replacement therapy in intensive care unit patients with acute kidney injury: A crossover randomized trial.

Cheng Hang1, Li-Jun Liu2, Zhao-Yun Huang1, Jian-Liang Zhu2, Bao-Chun Zhou2, Xiao-Zhen Li2.   

Abstract

BACKGROUND: The study aims to investigate an optimal indicator for changing the filter during the continuous renal replacement therapy (CRRT) in intensive care unit (ICU) patients with acute kidney injury (AKI).
METHODS: Patients with AKI requiring CRRT in an ICU were randomly divided into two groups for crossover trial, i.e., groups A and B. Patients in the group A were firstly treated with continuous veno-venous hemofiltration (CVVH), followed by continuous veno-venous hemodiafiltration (CVVHDF). Patients in the group B were firstly treated with CVVHDF followed by CVVH. Delivered doses of solutes with different molecular weights at the indicated time points between groups were compared. A correlation analysis between the delivered dose and pre-filter pressure (PPRE) and transmembrane pressure (PTM) was performed. Receiver operating characteristic (ROC) curves were constructed to evaluate the accuracy of PTM as an indicator for filter replacement.
RESULTS: A total of 50 cases were analyzed, 27 in the group A and 23 in the group B. Delivered doses of different molecular-weight solutes significantly decreased before changing the filter in both modalities, compared with those at the initiation of treatment (all P<0.05). In the late stage of CRRT, the possible rebound of serum medium-molecular-weight solute concentration was observed. PTM was negatively correlated with the delivered dose of medium-molecular-weight solute in both modalities. The threshold for predicting the rebound of serum concentration of medium-molecular-weight solute by PTM was 146.5 mmHg (1 mmHg=0.133 kPa).
CONCLUSIONS: The filter can be used as long as possible within the manufacturer's safe use time limits to remove small-molecular-weight solutes. PTM of 146.5 mmHg may be an optimal indicator for changing the filter in CRRT therapies to remove medium-molecular-weight solutes. Copyright: © World Journal of Emergency Medicine.

Entities:  

Keywords:  Acute kidney injury; Continuous renal replacement therapy; Delivered dose; Solute removal efficiency

Year:  2022        PMID: 35646215      PMCID: PMC9108922          DOI: 10.5847/wjem.j.1920-8642.2022.046

Source DB:  PubMed          Journal:  World J Emerg Med        ISSN: 1920-8642


  18 in total

1.  KDIGO clinical practice guidelines for acute kidney injury.

Authors:  Arif Khwaja
Journal:  Nephron Clin Pract       Date:  2012-08-07

2.  Actually delivered dose of continuous renal replacement therapy is underestimated in hemofiltration.

Authors:  Zhongheng Zhang; Hongying Ni; Haozhe Fan; Danyu Li; Xiao Xu
Journal:  ASAIO J       Date:  2013 Nov-Dec       Impact factor: 2.872

3.  Solute clearance in CRRT: prescribed dose versus actual delivered dose.

Authors:  William D Lyndon; Keith M Wille; Ashita J Tolwani
Journal:  Nephrol Dial Transplant       Date:  2011-09-05       Impact factor: 5.992

4.  International Survey on the Management of Acute Kidney Injury and Continuous Renal Replacement Therapies: Year 2018.

Authors:  Kumar Digvijay; Mauro Neri; Weixuan Fan; Zaccaria Ricci; Claudio Ronco
Journal:  Blood Purif       Date:  2018-09-28       Impact factor: 2.614

5.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.

Authors:  Andrew Rhodes; Laura E Evans; Waleed Alhazzani; Mitchell M Levy; Massimo Antonelli; Ricard Ferrer; Anand Kumar; Jonathan E Sevransky; Charles L Sprung; Mark E Nunnally; Bram Rochwerg; Gordon D Rubenfeld; Derek C Angus; Djillali Annane; Richard J Beale; Geoffrey J Bellinghan; Gordon R Bernard; Jean-Daniel Chiche; Craig Coopersmith; Daniel P De Backer; Craig J French; Seitaro Fujishima; Herwig Gerlach; Jorge Luis Hidalgo; Steven M Hollenberg; Alan E Jones; Dilip R Karnad; Ruth M Kleinpell; Younsuk Koh; Thiago Costa Lisboa; Flavia R Machado; John J Marini; John C Marshall; John E Mazuski; Lauralyn A McIntyre; Anthony S McLean; Sangeeta Mehta; Rui P Moreno; John Myburgh; Paolo Navalesi; Osamu Nishida; Tiffany M Osborn; Anders Perner; Colleen M Plunkett; Marco Ranieri; Christa A Schorr; Maureen A Seckel; Christopher W Seymour; Lisa Shieh; Khalid A Shukri; Steven Q Simpson; Mervyn Singer; B Taylor Thompson; Sean R Townsend; Thomas Van der Poll; Jean-Louis Vincent; W Joost Wiersinga; Janice L Zimmerman; R Phillip Dellinger
Journal:  Intensive Care Med       Date:  2017-01-18       Impact factor: 17.440

6.  Cost of acute renal replacement therapy in the intensive care unit: results from The Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) study.

Authors:  Nattachai Srisawat; Loredo Lawsin; Shigehiko Uchino; Rinaldo Bellomo; John A Kellum
Journal:  Crit Care       Date:  2010-03-26       Impact factor: 9.097

7.  Acute kidney injury enhances outcome prediction ability of sequential organ failure assessment score in critically ill patients.

Authors:  Chih-Hsiang Chang; Pei-Chun Fan; Ming-Yang Chang; Ya-Chung Tian; Cheng-Chieh Hung; Ji-Tseng Fang; Chih-Wei Yang; Yung-Chang Chen
Journal:  PLoS One       Date:  2014-10-03       Impact factor: 3.240

Review 8.  Nomenclature for renal replacement therapy in acute kidney injury: basic principles.

Authors:  Mauro Neri; Gianluca Villa; Francesco Garzotto; Sean Bagshaw; Rinaldo Bellomo; Jorge Cerda; Fiorenza Ferrari; Silvia Guggia; Michael Joannidis; John Kellum; Jeong Chul Kim; Ravindra L Mehta; Zaccaria Ricci; Alberto Trevisani; Silvio Marafon; William R Clark; Jean-Louis Vincent; Claudio Ronco
Journal:  Crit Care       Date:  2016-10-10       Impact factor: 9.097

9.  A Randomized, Single-Blind, Crossover Trial of Recovery Time in High-Flux Hemodialysis and Hemodiafiltration.

Authors:  James R Smith; Norica Zimmer; Elizabeth Bell; Bernard G Francq; Alex McConnachie; Robert Mactier
Journal:  Am J Kidney Dis       Date:  2016-12-23       Impact factor: 8.860

Review 10.  Design, analysis, and presentation of crossover trials.

Authors:  Edward J Mills; An-Wen Chan; Ping Wu; Andy Vail; Gordon H Guyatt; Douglas G Altman
Journal:  Trials       Date:  2009-04-30       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.